肿瘤患者医院感染产ESBLs大肠埃希菌临床分布与基因分析

发布时间：2018-11-14 07:38

【摘要】：目的了解本地区肿瘤患者医院感染产超广谱β-内酰胺酶(ESBLs)大肠埃希菌的临床分布及基因型,以指导临床医师合理选择抗菌药物。方法对2014年3月-2016年10月医院恶性肿瘤患者临床标本中分离出的338株产ESBLs大肠埃希菌的分布进行分析,同时随机抽取其中60株应用聚合酶链反应(PCR)方法分别扩增产ESBLs大肠埃希菌常见的β-内酰胺酶基因:TEM、CTX-M和SHV。结果分离的498株大肠埃希菌中,产ESBLs 338株,占67.87%;科室分布以妇瘤科为主,共94株占27.81%;PCR扩增显示,60株产ESBLs大肠埃希菌中,TEM55株,占91.67%,CTX-M1 42株,占70.00%,CTX-M13 42株,占70.00%,SHV24株占40.00%;且携带≥两种耐药基因53株占88.33%。结论本地区肿瘤患者医院感染产ESBLs大肠埃希菌主要分布在妇瘤科及胃肠科等科室;基因型以TEM、CTX-M1、CTX-M13型为主。
[Abstract]:Objective to investigate the clinical distribution and genotype of extended-spectrum 尾 -lactamase (ESBLs) producing Escherichia coli in nosocomial infection of tumor patients in order to guide clinicians to select antibiotics. Methods from March 2014 to October 2016, 338 strains of Escherichia coli producing ESBLs were isolated from clinical specimens of malignant tumor patients in hospitals. At the same time, 60 strains were randomly selected to amplify the 尾 -lactamase genes of ESBLs producing Escherichia coli by polymerase chain reaction (PCR), TEM,CTX-M and SHV., respectively. Results out of 498 strains of Escherichia coli, 338 strains (67.87%) produced ESBLs, and 94 strains (27.81%) were mainly distributed in the department. PCR amplification showed that among the 60 strains of Escherichia coli producing ESBLs, TEM55 strains accounted for 91.67% of CTX-M1 42, CTX-M13 42 strains, and SHV24 strains 40.002, and 53 strains carrying more than two resistant genes accounted for 88.33 strains. Conclusion the ESBLs Escherichia coli was mainly distributed in the department of gynecomatology and gastroenterology, and the genotype was TEM,CTX-M1,CTX-M13 type in the tumor patients with nosocomial infection.
【作者单位】：广西医科大学附属肿瘤医院检验科;
【基金】：广西自然科学基金资助项目(2014GXNSFAA118066) 广西卫计委科研基金资助项目(Z2015598) 广西教育厅科研基金资助项目(KY2015LX055)
【分类号】：R730.43

【参考文献】